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Abstract
Some bacterial strains of the multidrug-resistant Gram-positive bacteria Enterococcus faecalis can significantly reduce the
efficacy of conventional antimicrobial chemotherapy. Thus, the introduction of bacteriophage (phage) therapy is expected,
where a phage is used as a bioagent to destroy bacteria. E. faecalis phage WEF24C is known to be a good candidate for a
therapeutic phage against E. faecalis. However, this therapeutic phage still produces nonuniform antimicrobial effects with
different bacterial strains of the same species and this might prove detrimental to its therapeutic effects. One solution to
this problem is the preparation of mutant phages with higher activity, based on a scientific rationale. This study isolated and
analyzed a spontaneous mutant phage, WEF24C-P2, which exhibited higher infectivity against various bacterial strains when
compared with phage WEF24C. First, the improved bactericidal effects of phage WEF24C-P2 were attributable to its
increased adsorption rate. Moreover, genomic sequence scanning revealed that phage WEF24C-P2 had a point mutation in
orf31. Proteomic analysis showed that ORF31 (mw, 203 kDa) was present in structural components, and immunological
analysis using rabbit-derived antibodies showed that it was a component of a long, flexible fine tail fiber extending from the
tail end. Finally, phage WEF24C-P2 also showed higher bactericidal activity in human blood compared with phage WEF24C
using the in vitro assay system. In conclusion, the therapeutic effects of phage WEF24C-P2 were improved by a point
mutation in gene orf31, which encoded a tail fiber component.
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Introduction
Enterococcus species are opportunistic pathogens. Vancomycin-
resistant Enterococcus (VRE) species are medically important
because they fail to respond to conventional antimicrobial
chemotherapy and cause fatal infections in nosocomial settings.
An increase in the number of VRE cases has been reported
worldwide, and E. faecalis is the most frequent clinically isolated
species in enterococcal infections [1–6]. Although the situation is
critical, antimicrobial agents with new modes of action are unlikely
to be developed because there is little commercial interest in
producing novel antibiotics or in developing novel technology
[7,8]. Therefore, to combat this bacterium, an alternative
therapeutic approach to antibiotics must be explored. One of
the favored alternative therapies to antibiotics is phage therapy,
which uses bacteriophages (bacterial viruses) as selective bioagents
to destroy the targeted bacteria.
In addition to its effectiveness against drug-resistant bacteria,
phage therapy has many superior characteristics compared with
antibiotics, including the phage targeting ability, multiplication at
the site of infection, and fewer side effects [9–11]. However, phage
therapy is not always ideal because, just as different bacterial
strains show different levels of antibiotic sensitivity, different strains
also vary in their sensitivity to phage [12,13]. The sensitivity of
bacteria to phage can be measured as phage infectivity for a
bacterial strain; this can be expressed as the relative efficiency of
plating (EOP), which is the ratio of plaque-forming units (pfu) of
phage plated on a particular bacterial strain to the pfu of phage
plated on a standard strain. EOP variation may influence the
therapeutic effects. In some cases, bacterial strain with low EOP
may not result in the desired clinical outcome.
Phages with strong lytic activity and a broad host range are
generally used in phage therapy. We have previously reported an
E. faecalis phage WEF24C with strong lytic activity and an
extremely broad spectrum of hosts. This phage belongs to the
family Myoviridae and the genus of SPO1-like viruses, which are
common member lytic phages that have been applied in phage
therapy [14–17]. Previous analysis of phage WEF24C using in
silico, in vitro, and in vivo methods indicated the safety and
therapeutic effects of phage WEF24C, so it was eligible as a
therapeutic phage candidate [16–18]. However, the therapeutic
effect of phage WEF24C varies between different bacterial strains.
For example, phage WEF24C infected the E. faecalis strain EF14 at
a rate ca. 32 times higher than for the vancomycin-resistant E.
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of phage WEF24C to rescue 100% of mice infected with strain
VRE2 compared with strain EF14 [18].
In the future, it is expected that highly active phages will be
produced by genetic recombination or natural mutation with the
support of a sound scientific rationale [9,19], and so some efforts
have recently been initiated [20–25]. This demands greater
accumulation of knowledge regarding phage biology, particularly
study of SPO1-like viruses. To address this goal, the analysis of
highly active mutant phages with improved therapeutic efficacy
could be used as a shortcut in the development of therapeutic
phage technology. In the current study, a spontaneous mutant
phage with improved therapeutic efficacy was isolated from the
therapeutic candidate phage WEF24C. The molecular causes of its
enhanced efficacy were explored by comparison with phage
WEF24C.
Materials and Methods
Bacteria and phage culture and plasmids
Thirty-five E. faecalis strains are described in Table 1. Escherichia
coli strains DH5a and BL21 were used for cloning and protein
overexpression. E. faecalis phage WEF24C is described elsewhere
[16–18]. pUC18 and pCold II plasmids were purchased from
Takara Bio (Kyoto, Japan) for the purposes of cloning and protein
overexpression, respectively.
Tryptic soy broth (TSB) was used as a culture medium for E.
faecalis and phage WEF24C. Luria–Bertani (LB) medium contain-
ing 100 mgm L
21 ampicillin was used as a culture medium for Esc.
coli harboring the appropriate plasmid. All bacteria and phage
incubations were conducted in a TSB medium at 37uC, unless
otherwise stated. Phages were cultured in either liquid media or
double-layered agar with the appropriate E. faecalis bacterial strain.
In the double-layered agar method, 100 mL of bacterial overnight
culture was plated with or without 100 mL of phage suspension.
Unless otherwise stated, all culture media and reagents used in
this study were purchased from Becton, Dickinson and Co.
(Sparks, MD, USA), and Nacalai Tesque Inc. (Kyoto, Japan),
respectively.
Isolation of the E. faecalis phage WEF24C spontaneous
mutant
Phage WEF24C was diluted to approximately 1.0610
4 pfu mL
21,
and 100 mL of the diluted phage was plated with the E. faecalis strain
VRE2. A large clear plaque was purified at least three times.
Plaque sizes were compared to examine the difference between
wild-type and mutant phages. After incubation of wild-type or
mutant phage on the double-layered agar with E. faecalis strain
VRE2, the bacterial lawn was stained with 2% 2,3,5,-triphenylte-
trazolium chloride. The phage plaques were photographed with a
scale, and then the size of the plaques was measured using the
scale.
Measurement of phage infectivity
Plaque-forming ability was determined using a streak test. A dip
of phage suspension was streaked onto bacteria-inoculated double-
layered agar. After 12 h incubation, plaque forming or ‘‘lysis from
without’’ was determined based on the morphology and degree of
bacterial inhibition halos formed by the phage. This assay was
conducted with all E. faecalis strains, and the plaque-forming ability
with different E. faecalis strains was summarized according to host
range.
The plaque-forming ability with various E. faecalis strains was
quantified by relative EOP. The number of plaques was
standardized as one for E. faecalis strain EF24, and then the
relative EOP of other E. faecalis strains was calculated.
The adsorption rate, latent period, and burst size were
determined, using previously described methods [26–28].
Phage culture and purification
The phage was cultured with E. faecalis strain EF24 in 300 mL
of TSB. After the complete lysis of E. faecalis, the phage lysate was
collected by centrifugation at 10,0006g for 10 min at 4uC.
Polyethylene glycol 6000 (10%) and 0.5 M NaCl were supple-
mented to the final concentration and the mixture was left
overnight at 4uC. After centrifugation at 10,0006g for 40 min at
4uC, the phage pellet was dissolved in TM buffer (10 mM Tris-
HCl, pH 7.2; 5 mM MgCl2) containing 50 mgm L
21 of DNase I
(Sigma-Aldrich, St. Louis, MI, USA) and RNase A (Sigma-
Aldrich), before incubating at 37uC for 30 min. The phage
suspension was then placed on top of a discontinuous cesium
chloride (CsCl) density gradient (r=1.3, 1.5, and 1.7) and
centrifuged at 50,0006g for 2 h at 4uC. The phage bands were
collected and purified again using CsCl density gradient
ultracentrifugation. The phage band was collected and dialyzed
against AAS (0.1 M ammonium acetate, 10 mM NaCl, 1 mM
CaCl2, 1 mM MgCl2, pH 7.2) for 1 h at 4uC.
Genomic analysis of mutant phage
The genomic DNA of the mutant phage was extracted using a
previously described method [17]. Briefly, the purified phage
sample containing CsCl was diluted fourfold with AAS and
pelleted by ultracentrifugation at 100,0006g for 1 h at 4uC. The
phage pellet was suspended in protein lysis buffer (1% SDS;
20 mM Tris-HCl, pH 8.0; 50 mM EDTA; 0.2 mg/mL proteinase
K, Takara Bio) and incubated for 1 h at 55uC. Phenol extraction
and ethanol precipitation were conducted, and then the genomic
DNA was solubilized in water.
The whole genome was amplified by PCR with primers (Table
S1) using LaboPass SP-Taq (Hokkaido System Science, Hokkaido,
Japan), according to the manufacturer’s instructions. The PCR
products were then purified and sequenced by primer walking with
a BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems,
Foster City, CA, USA), according to the manufacturer’s instruc-
tions, using an ABI PRISM 3100-Avant Genetic Analyzer (Applied
Biosystems). Sequencing primers are listed in Table S2. Any
misreads on the raw data were manually corrected. The sequencing
results were assembled using ATGC sequence assembly software
(Genetyx Corporation, Tokyo, Japan) and the whole genome was
assembled with at least 16sequence coverage. During mutation site
scanning, the mutant phage genome sequence was aligned with the
genome sequence of phage WEF24C (GenBank accession
no. AP009390.1), using ATGC sequence assembly software
(Genetyx Corporation). The mutant phage WEF24C-P2 genome
was deposited into GenBank (accession no. AB609718).
Bioinformatics analysis of proteins
The theoretical molecular weight (mw) and the isoelectric point
(pI) of the proteins were calculated using Genetyx version 10
(Genetyx Corporation). Homology searches in public databases
were conducted using the protein Basic Local Alignment Search
Tool (BLASTP) at the National Center for Biotechnology
Information (NCBI; http://www.ncbi.nlm.nih.gov/). The protein
signature was also analyzed with InterProScan (http://www.ebi.
ac.uk/Tools/InterProScan/).
The ORF arrangements were compared using Genome
Matcher software (http://www.ige.tohoku.ac.jp/joho/gmProject/
gmhomeJP.html) [29]. Compared genomes were retrieved from
Phage with Increased Adsorption
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phage K, AY176327; Staphylococcus phage G1, AY954969; Listeria
phage A511, DQ003638; Lactobacillus phage LP65, AY682195;
Bacillus phage SPO1, FJ230960; Lactobacillus phage WLb338-1,
FJ822135) [30–34].
Cloning and overexpression of the recombinant protein
The coding sequences of gp31:2640–4150 and gp31:3680–5200
were amplified by PCR (LaboPass SP-Taq kit) using the
appropriate primer sets (Table S3) and with the genomic DNA
of phage WEF24C as a template, following the manufacturer’s
instructions. The terminal regions of the PCR products were
digested with the restriction enzymes HindIII and SacI (Takara
Bio) and cloned into the plasmid pUC18. The accurately cloned
fragment was then excised by HindIII and SacI, and recloned into
the plasmid pCold II. The plasmids were transformed into Esc. coli
strains DH5a and BL21 for the purposes of cloning and protein
expression, respectively.
Table 1. E. faecalis strains used in this study and phage infectious activity.
Efficiency of plating
(EOP)
E. faecalis
strain Description
a Isolated source
Phage WEF24C
activity
Phage WEF24C-P2
activity WEF24C WEF24C-P2
EOP relative rate
(WEF24C-P2/WEF24C)
ATCC19433 ATCC standard strain ## 0.78 0.64 0.82
EF1 Clinical isolate from KUH Vaginal discharge ## 1.40 2.70 1.93
EF2 Clinical isolate from KUH Vaginal discharge ## 0.80 2.00 2.50
EF3 Clinical isolate from KUH Sputum ## 0.50 0.80 1.60
EF4 Clinical isolate from KUH Pharyngis – –
EF5 Clinical isolate from KUH Skin ## 0.90 2.50 2.78
EF6* Clinical isolate from KUH Urine ## 0.06 1.50 25.00
EF7 Clinical isolate from KUH Eye discharge ## 1.40 2.50 1.79
EF8 Clinical isolate from KUH Other ## 0.70 2.20 3.14
EF9* Clinical isolate from KUH Urine ## 0.10 2.60 26.00
EF10 Clinical isolate from KUH Other ## 1.00 2.80 2.80
EF11* Clinical isolate from KUH Urine ## 0.08 1.70 21.25
EF12* Clinical isolate from KUH Urine ## 0.06 2.20 36.67
EF13 Clinical isolate from KUH Pharyngis – –
EF14 Clinical isolate from KUH Vaginal discharge ## 1.00 1.30 1.30
EF15 Clinical isolate from KUH Pus – –
EF16 Clinical isolate from KUH Vaginal discharge ## 0.80 2.60 3.25
EF17 Clinical isolate from KUH Vaginal discharge ## 0.60 1.60 2.67
EF18 Clinical isolate from KUH Vaginal discharge ## 0.90 1.00 1.11
EF19 Clinical isolate from KUH Vaginal discharge ## 1.40 3.00 2.14
EF20 Clinical isolate from KUH Pus ## 0.20 1.00 5.00
EF21 Clinical isolate from KUH Pus ## 1.00 1.50 1.50
EF22 Clinical isolate from KUH Mouthwash ## 1.20 1.70 1.42
EF23 Clinical isolate from KUH Sputum ## 0.20 1.20 6.00
EF24 Clinical isolate from KUH Vaginal discharge ## 1.00 1.00 1.00
EF25 Clinical isolate from KUH Other ## 1.00 1.50 1.50
EF26 Clinical isolate from KUH Vaginal discharge ## 0.90 1.10 1.22
EF27 Clinical isolate from KUH Eye discharge ## 0.80 0.50 0.63
EF28 Clinical isolate from KUH Vaginal discharge ## 0.70 1.20 1.71
EF29 Clinical isolate from KUH Pus ## 0.70 1.40 2.00
EF30 Clinical isolate from KUH Vaginal discharge – –
VRE1 VRE strain Sputum ## 0.22 1.46 6.64
VRE2* VRE strain Urine ## 0.03 1.61 50.31
VRE3* VRE strain Urine ## 0.05 1.46 30.42
VRE4* VRE strain Rectal swab ## 0.02 1.57 65.42
aKUH represents Kochi University Hospital; all VRE strains were isolated from Nagano Hokushin Hospital, Nagano, Japan.
‘‘#’’ indicates plaque forming, and ‘‘–’’ indicates ‘‘lysis from without’’ or no lysis.
*E. faecalis strain with relative EOP rates greater than 10 (WEF24C-P2 EOP/WEF24C).
Measurements were conducted twice and representative data are shown here.
doi:10.1371/journal.pone.0026648.t001
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coli BL21 containing an appropriate plasmid, which was grown
exponentially to an optical density of 0.5–0.7 at 600 nm, and left
for 30 min at 15uC. The growth medium was supplemented with
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and bacteria
were cultured aerobically for 24 h at 15uC. After centrifugation at
60006g for 10 min at 4uC, the supernatant was decanted and the
cell pellet was stored at 280uC until use. To check the
overexpression of the recombinant protein in Esc. coli, the cell
pellet was dissolved in Laemmli’s sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE) sample buffer, boiled
for 5 min, and centrifuged at 20,0006g for 5 min at 4uC. The
supernatants of IPTG-induced and non-IPTG-induced samples
were separately electrophoresed using a 12.5% SDS-PAGE gel
and stained using Coomassie brilliant blue R-250 to confirm
protein overexpression.
Purification of the recombinant protein
BL21 (pCold II gp31:2640–4150) or BL21 (pCold II gp31:3680–
5200) were prepared from 250 mL cultures and resuspended in
20 mL lysis buffer (6 M urea, 100 mM sodium phosphate,
300 mM NaCl, pH 7.8) and sonicated (48 pulses65s a t 5s
intervals) on ice. After centrifugation at 10,0006g for 20 min at
20uC, the supernatant was added to 1 mL Talon metal affinity
resin (Clontech Laboratories, Mountain View, CA, USA) and
gently mixed for 90 min at room temperature. The resin was
transferred to a column and was eluted with a wash buffer (6 M
urea, 100 mM sodium phosphate, 300 mM NaCl, pH 6.0),
followed by the same buffer supplemented with 5 mM imidazole.
The elute was collected after the application of 150 mM
imidazole-supplemented buffer. Protein purity was analyzed using
a 12.5% SDS-PAGE gel with Coomassie brilliant blue R-250
staining.
Protein renaturation was attempted by dialysis. First, the protein
was dialyzed against 1 M urea in phosphate buffer saline (PBS,
pH 7.2). GP31:2640–4150 was dialyzed against 0.5 M urea in
PBS, and GP31:3680–5200 was dialyzed against PBS several times
to remove urea. The protein was quantified using a Bradford
reagent (Sigma-Aldrich).
Antiserum of ORF31
Female New Zealand white rabbits (11 weeks, 2 kg) were
purchased from SLC Japan (Shizuoka, Japan). The experiments
were conducted with the approval of the Animal Experiment
Committee of Kochi University (permit no., D-00022). Different
rabbits were subcutaneously immunized with 0.5 mg of
GP31:2640–4150 in PBS containing 0.5 M urea, or GP31:3680–
5200 in PBS, emulsified with complete Freund’s adjuvant. Next,
the same rabbit was subcutaneously immunized five times at two-
week intervals with 0.25 mg of GP31:2640–4150 in PBS
containing 0.5 M urea, or GP31:3680–5200 in PBS, emulsified
with incomplete Freund’s adjuvant. After a sixth immunization
with incomplete Freund’s adjuvant, the presence of ORF31-
specific antibody in the serum was checked by Western blotting
against the IPTG-induced BL21 (pCold II gp31:2640–4150)o r
BL21 (pCold II gp31:3680–5200). Blood samples were taken one
week after the last immunization. The collected blood was
incubated overnight at room temperature, and the serum was
obtained by centrifugation at 23006g for 15 min at room
temperature. The serum was stored at 280uC until use.
Western blotting
After electrophoresis using a 6% or 12.5% SDS-PAGE gel, the
separated proteins were transferred to polyvinylidene fluoride
(PVDF) membranes (Immobilon-P Membrane; Millipore, Bill-
erica, MA, USA) using blotting solution (10 mM CHAPS, pH 11;
10% methanol) in a Hoefer TE70 semidry transfer unit (Hoefer
Inc., San Francisco, CA, USA) at 1 mA cm
2 21 for 90 min. The
blotted membrane was blocked with 1% skim milk in PBS, with
0.05% Tween 20 (PBS-T), at 4uC overnight and washed with PBS-
T( 3 610 min).
The membrane was incubated with either anti-GP31:2640–
4150 or anti-GP31:3680–5200 rabbit antiserum, diluted 1:5000
with 1% skim milk in PBS-T for 1 h at room temperature. The
membranes were washed (3610 min) in PBS-T. The membrane
was incubated with a secondary anti-rabbit immunoglobulin G
HRP-linked whole antibody (GE Healthcare, Buckinghamshire,
UK), which was diluted 1:100,000 with 1% skim milk in PBS-T,
for 30 min at room temperature. The membranes were washed
(3610 min) in PBS-T.
Immunoblot signals were detected using the ECL Plus Western
blotting detection system (GE Healthcare) and visualized using X-
ray films (Fuji Medical X-ray film, Fujifilm Corporation, Tokyo,
Japan).
Analysis of structural proteins
An equal volume of 26Laemmli’s sample bufferwas added to the
purified phage in AAS and boiled for 10 min. The phage proteins
were electrophoresed using either a 6% or a 12.5% SDS-PAGE gel,
with a standard prestained XL-Ladder marker (APRO Life Science
Institute, Tokushima, Japan). Structural proteins were visualized by
staining the gel with either 2D-silver stain reagent II (Daiichi Pure
Chemicals, Tokyo, Japan) or Coomassie brilliant blue R-250.
Western blotting was conducted using anti-GP31 rabbit sera.
Protein concentration
The purified phage in AAS, which was obtained from 1 L
culture, was heated for 5 min at 100uC. After cooling to 4uC, the
sample was treated with 10 mgm L
21 DNase I for 20 min at 37uC.
46Laemmli’s sample buffer was added before heating for 5 min
at 100uC. Protein with a molecular weight of more than 100 kDa
were concentrated by a centrifugal ultrafiltration using a Vivaspin
4 100000 MWCO (Sartorius Stedim Biotech, Go ¨ttingen, Ger-
many) (70006g, room temperature), until the volume was reduced
to 400 mL. The supernatant was collected and electrophoresed
using a 6% SDS-PAGE gel, before further analysis was conducted.
N-terminal sequencing
After electrophoresis of the concentrated proteins on a 6% SDS-
PAGE gel, the proteins were blotted onto the PVDF membrane
(Sequi-Blot PVDF Membrane; Bio-Rad Laboratories, Hercules,
CA, USA) using blotting solution (10 mM CHAPS, pH 11; 10%
methanol) with a Hoefer TE70 semidry transfer unit (Hoefer Inc.)
at 1.2 mA cm
2 21 for 180 min at 4uC. The blotted membrane was
stained with Coomassie brilliant blue R-250. The targeted protein
band was excised from the membrane and sequenced using a
PPSQ-31A/33A protein sequencer (Shimadzu, Kyoto, Japan).
The amino acid sequence was analyzed by in-house BLASTP
search against the phage WEF24C genome using In-silico
Molecular Cloning genomics edition (In-silico Biology, Yokohama,
Japan). The protein sequence was deposited in the UniProt
database (accession no. SPIN000005852).
Matrix assisted laser desorption ionization (MALDI)-time
of flight (TOF)/TOF analysis
The concentrated proteins were electrophoresed using a 6%
SDS-PAGE gel, and the gel was stained by colloidal Coomassie G-
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ammonium sulfate, 10% phosphoric acid, 20% methanol)
overnight at room temperature [35]. After destaining with MilliQ
water, the targeted protein band was excised. The gel was
incubated in a destaining solution (200 mM NH3HCO3, 50%
acetonitrile) for 30 min at 37uC, and the destaining solution was
replaced. This procedure was repeated until the gel was clear. The
gel was then sequentially incubated with a reduction solution
(10 mM dithiothreitol, 50 mM NH3HCO3) for 30 min at 50uC
and an alkylating solution (55 mM 2-iodoacetamide, 50 mM
NH3HCO3) for 60 min at 37uC in the dark. After reduction and
alkylation of the protein, the gel was rinsed by 50 mM NH3HCO3
for 10 min at room temperature. The gel was vortexed in 50 mM
NH3HCO3 for 5 min, and then again in acetonitrile for 5 min,
before being dried by vacuum centrifugation. The dried gel was
soaked in a digestion solution (12.5 ng mL
21 trypsin gold, mass
spectrometry grade, Promega, Madison, WI, USA; 50 mM
NH3HCO3, 0.1% n-octyl-b-glucoside) on ice for 45 min. The
gel was then incubated overnight in 50 mM NH3HCO3-0.1% n-
octyl-b-glucoside at 37uC. The digested peptides were extracted by
sonication in 50% acetonitrile and 70% acetonitrile in 0.1%
trifluoroacetic acid. The sample was concentrated by vacuum
centrifugation and suspended in 5% acetonitrile–0.1% trifluor-
oacetic acid. The sample was desalted using StageTips (C18
material, 20 mL tip; Proxeon, Odense C, Denmark) and dried by
vacuum centrifugation. Samples were dissolved in 5% acetoni-
trile–0.1% trifluoroacetic acid and cospotted with an equal volume
of the matrix (a-cyano-4-hydroxycinnamic acid dissolved in a
mixture of 50% acetonitrile–0.1% trifluoroacetic acid in a
saturated solution) onto a sample plate.
Finally, the sample was analyzed using an AB SCIEX TOF/
TOF 5800 System (AB Sciex, Foster City, CA, USA). The top 20
peaks from the TOF MS analysis were analyzed by tandem mass
spectrometry (MS/MS). A protein database for phage WEF24C
was constructed locally from the phage WEF24C genomic data in
this study. The MS/MS data were analyzed by Paragon method
using the ProteinPilot 3.0 software (AB Sciex) [36].
Antibody purification
The recombinant protein GP31:3680–5200 was coupled to a
Hi-Trap NHS-activated HP column (GE Healthcare) and the
antibody purification was conducted according to the manufac-
turer’s instructions. The purity of the antibody was checked by
SDS-PAGE, and the protein concentration of the antibody was
determined using Bradford reagent. The method obtained
0.4 mg mL
21 of purified anti-GP31:3680–5200 antibody.
Electron microscopy and immunoelectron microscopy
Electron microscopy was conducted by loading a drop of the
purified phage WEF24C in AAS onto formvar-carbon-coated
copper grids for 2 min, and absorbing the phage solution using
filter paper (Advantec Toyo, Tokyo, Japan). MilliQ water was then
loaded onto the phage-loaded copper grids for 2 min, and the
water was again absorbed using filter paper (Advantec Toyo). This
treatment with MilliQ water is referred to as a wash in this study,
and two washes were conducted after phage loading. The copper
grids were then negatively stained with 2% uranyl acetate
(pH 4.0).
Immunoelectron microscopy was conducted by incubating the
purified phage with anti-GP31:3680–5200 antibody diluted with
PBS (1:100) for 30 min at room temperature. The samples were
then loaded onto formvar-carbon-coated copper grids. Each
copper grid was washed once with MilliQ water, and then
incubated with 12 nm colloidal gold-AffiniPure goat anti-rabbit
IgG (H+L) (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) in PBS (1:50) for 30 min at 37uC. Each grid was then
washed twice with MilliQ water and negatively stained with 2%
uranyl acetate (pH 4.0).
Electron micrographs were acquired using a Hitachi H-7100
transmission electron microscope (Hitachi, Ibaraki, Japan) at
100 kV.
Measurements of therapeutic efficacy in vitro
E. faecalis strain EF11 at mid-log phase was washed with saline
three times. The bacteria were suspended in saline, and bacterial
concentration (bacteria mL
21) was determined by turbidity (in
Klett units), measured using a Klett-Summerson photoelectric
colorimeter (Klett Manufacturing Co., NY, USA). Phage was
prepared at an appropriate concentration, diluted with TSB.
A bacterial suspension was prepared at a concentration of ca.
3.0610
9 bacteria mL
21. The phage suspension was ca.
3.0610
7 pfu mL
21. Five microliters of bacterial suspension and
5 mL of phage suspension were mixed with 140 mL TSB in one
well of a 96-well microtiter plate. The plate was incubated with
shaking at 37uC and the turbidity was measured every 15 min at
600 nm, using a HiTS incubation reader (Scinics Corporation,
Tokyo, Japan).
A bacterial suspension of ca. 1.5610
10 bacteria mL
21 was
prepared. Phage was diluted with TSB and a suspension of ca.
1.5610
8 pfu mL
21 was prepared. Human blood from a healthy
male volunteer donor was collected into a heparinized blood
collection tube. Five microliters of the bacterial suspension and
5 mL of phage suspension were mixed with 900 mL of human
blood, and the mixture was incubated. After incubation for one
day at 37uC, the blood culture was diluted and plated. After
incubation overnight, a colony count was conducted.
Statistical analysis
All statistical analyses were performed using GraphPad InStat
version 3 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Large-plaque-forming spontaneous mutant phage
WEF24C-P2
Phage WEF24C was plated onto E. faecalis strain VRE2 and a
large-plaque-forming spontaneous mutant phage WEF24C-P2 was
isolated (Figure 1). The plaque sizes of wild-type phage WEF24C
and mutant phage WEF24C-P2 were 0.7460.33 mm and
361.21 mm (mean 6 SD; n=20), respectively. The plaque sizes
formed by phages WEF24C and WEF24C-P2 were significantly
different (Mann-Whitney U test; P,0.0001). We hypothesized that
the difference in the plaque size was because of the improved
infectious ability of mutant phage WEF24C-P2.
Host range and phage infectivity were compared with various
clinical E. faecalis strain isolates to determine whether the mutant
phage had enhanced infectious ability. There was no difference in
the host range between the wild-type phage WEF24C and the
mutant phage WEF24C-P2. On the other hand, phage infectivity
with various bacterial strains was evaluated by comparing the
EOP of the wild-type phage WEF24C and the mutant phage
WEF24C-P2. E. faecalis strain EF24 was used as a reference strain
in the EOP assay, because phages WEF24C and WEF24C-P2 were
adapted to this bacterial strain and formed clear countable plaques
with this strain. The mutant phage WEF24C-P2 had an improved
EOP compared with the wild-type phage WEF24C (Table 1). The
mutant phage WEF24C-P2 showed a tenfold increase in EOP
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isolated from urine in this study.
Improved phage adsorption
Enhancement of key stages affecting the phage life cycle, i.e.,
adsorption, latent period, and burst size, were likely to account for
the greater infectivity of phage WEF24C-P2 [37]. Previous studies
using E. faecalis strain EF24 as a reference strain found that the
adsorption rate was 90% in 5 min. The latent period and the burst
size of phage WEF24C are known to be ca. 30 min and ca. 110–
120, respectively. The latent period and burst size can be
evaluated by comparing the phage production rate 55 min post
infection between wild-type phage WEF24C and mutant phage
WEF24C-P2. Therefore, the phage adsorption rate at 5 min and
the phage production rate 55 min post infection were compared
for the wild-type phage WEF24C and the mutant phage WEF24C-
P2, using E. faecalis strain EF24.
The phage production rates 55 min post infection did not differ
significantly between the wild-type phage WEF24C and the mutant
phage WEF24C-P2 (Figure 2A). By contrast, adsorption rates
5 min after phage inoculation were significantly different between
the wild-type WEF24C and the mutant phage WEF24C-P2
(Figure 2B), although the difference was small.
Figure 1. Plaque formation of wild-type phage WEF24C and
mutant phage WEF24C-P2 with E. faecalis strain VRE2. (A) Plaques
formed by wild-type phage WEF24C. (B) Plaques formed by mutant
phage WEF24C-P2. The bar indicates 10 mm. Photographs were taken
after incubation for 12 h at 37uC. Mutant phage WEF24C-P2 formed
larger plaques than wild-type phage WEF24C.
doi:10.1371/journal.pone.0026648.g001
Figure 2. Comparison of the infectivity of phage WEF24C and phage WEF24C-P2.N and # indicate wild-type phage WEF24C and mutant
phage WEF24C-P2, respectively. On the graphs, error bars indicate SD. Statistically significant differences are indicated by an asterisk. (A) Phage
production 55 min post infection of E. faecalis strain EF24. Phages WEF24C (n=6) and WEF24C-P2 (n=6) were not significantly different (Mann-
Whitney U test; P=0.3939). (B) Phage adsorption in 5 min to E. faecalis strain EF24. Phages WEF24C (n=6) and WEF24C-P2 (n=6) were significantly
different (Mann-Whitney U test; P,0.005). (C) EOP with E. faecalis strain EF11. Phages WEF24C (n=8) and WEF24C-P2 (n=8) were significantly
different (Mann-Whitney U test; P,0.0005. (D) Phage adsorption in 5 min to E. faecalis strain EF11. Phages WEF24C (n=6) and WEF24C-P2 (n=6) were
significantly different (Mann-Whitney U test; P,0.005).
doi:10.1371/journal.pone.0026648.g002
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phage WEF24C-P2 adsorption in 5 min using E. faecalis strain
EF11, which is a bacterial strain with a lower EOP, i.e., more
sensitive to phage WEF24C-P2 than to phage WEF24C (Figure 2C
and 2D). The adsorption efficiency of phage WEF24C-P2 was
significantly higher than that of phage WEF24C. Thus, the mutant
phage WEF24C-P2 was considered to have an improved
adsorption efficiency.
A spontaneous point mutation found on a large putative
gene
The whole genome sequence of the mutant phage WEF24C-P2
was screened to search for the causative genetic factor. Only a
single point mutation in the nucleotide 31,966 on orf31 was
discovered (Figure 3) by comparing the whole genome sequence
for the mutant phage WEF24C-P2 and the wild-type phage
WEF24C. The guanine (G) residue at nucleotide 31,966 in the
wild-type phage WEF24C was changed to adenine (A) in the
mutant phage WEF24C-P2, which would result in replacing a
single negatively charged glutamic acid (E) in ORF31 of the wild-
type phage WEF24C with a positively charged lysine (K) in the
mutant phage WEF24C-P2 (Figure 3).
Bioinformatics analysis of the putative ORF31 protein
ORF31 was predicted to be a large protein composed of 1825
amino acids (theoretical mw, 203 kDa; theoretical pI, 4.7). There
had been frequent data updates in GenBank since the first report
of the phage WEF24C genome, so the BLASTP analysis of ORF31
was conducted again. Overall, the N-terminal region of ORF31
was similar to the N-terminal region of hypothetical proteins with
unknown function in most SPO1-like viruses. Among them, only
Lactobacillus phages WLb338-1 and LP65 seemed to have similar
large proteins: ORF122 (theoretical mw, 235 kDa; theoretical pI,
4.82) and ORF97 (theoretical mw, 221 kDa; theoretical pI, 4.91),
respectively [30,31]. 52% of the ORF31 at the N-terminal showed
similarity to ORF122 of Lactobacillus phage WLb338-1, with an E-
value of 2e-114, whereas 16% of the ORF31 at the N-terminal
showed similarity to ORF97 of Lactobacillus phage LP65, with an
E-value of 8e-13 (Figure 3 and Figure S1). The protein sequence,
mw, and pI of the protein were similar, so ORF31 may be
functionally similar to ORF122 of Lactobacillus phage WLb338-1.
No significant protein domains was not predicted by Inter-
ProScan and no similar proteins with known function were found
by the BLASTP search of the NCBI, so the function of ORF31
was difficult to predict. Thus, the similar ORF122 protein found in
phage WLb338-1 was analyzed to facilitate protein function
prediction (Figure S1). The C-terminal region of phage WLb338-1
ORF122 was predicted by bioinformatics to have not only the
galactose binding domain-like superfamily and similar protein
sequences to the putative host specificity proteins. Taking into
account the mw, bioinformatics analysis, and the association of
ORF31 with adsorption in the mutant phage analysis, it was
hypothesized that ORF31 could be a component of a tail fiber.
Identification of ORF31 as a phage structural protein
ORF31 was annotated as a large protein, and the bioinformatic
analysis suggested that it could be a tail fiber. However, it was not
certain if such a large protein was present in the structural
proteins. Moreover, if present, mRNA splicing or posttranslational
modification could occur and the mw of the protein might be
significantly smaller than predicted. Thus, Western blotting was
conducted to test for the presence of ORF31 in the phage
structural proteins with the predicted mw. Before the start of the
experiment, anti-ORF31 sera were produced by immunization of
rabbits with the recombinant proteins GP31:2640–4150 and
GP31:3680–5200 (Figure S2). The anti-GP31:2640–4150 or anti-
GP31:3680–5200 rabbit serum was used in Western blotting,
which was performed with phage WEF24C structural proteins
separated on 12.5% and 6% SDS-PAGE gels. The results of the
Western blot analysis showed that the ORF31 was present as a
protein of ca. 183 kDa. Comparison of the mw detected in the
Western blot with the mw of the structural proteins in the SDS-
PAGE analysis showed that the protein detected in the Western
Figure 3. Mutation site in orf31 of phage WEF24C-P2 and the features of ORF31 and neighboring ORFs. The mutation site is shown in
the DNA alignments between phage WEF24C and phage WEF24C-P2, in the bottom row. A point mutation (i.e., substitution) was found on the
putative gene orf31, where the nucleotides are shown in red. The point mutation changed an amino acid from glutamic acid (negatively charged
amino acid; wild-type phage WEF24C) to lysine (positively charged amino acid; mutant phage WEF24C-P2), which is colored and boxed in green. The
partial genomic map of phage WEF24C is shown in the top row. The arrows indicate each ORF. The arrows in yellow indicate ORFs with similarity to
other phage proteins. The region colored in purple, the N-terminal region of the ORF31, is similar to the N-terminal region of ORF122 of Lactobacillus
paracasei phage WLb338-1, with an E-value of 1.0610
2114 in the BLASTP analysis. It occupied 53% of the ORF31 protein sequence. A mutation site is
denoted by an asterisk around the C-terminal region of the ORF31, but no protein signature was found. ORF32–34 did not show similarity to the
other proteins.
doi:10.1371/journal.pone.0026648.g003
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SDS-PAGE gel stained by silver staining (Figure 4A and 4B).
However, the protein was barely detected by Coomassie brilliant
blue R-250 staining. Thus, the protein was considered to be
expressed in very small quantities relative to other WEF24C
structural proteins.
To validate the presence of ORF31 in the structural proteins,
the protein detected by the Western blot was analyzed further.
The low levels of the target protein meant that the structural
proteins had to be concentrated by centrifugal ultrafiltration
before analysis by MALDI-TOF/TOF and N-terminal sequenc-
ing (Figure 4C). After separation of the concentrated structural
proteins using a 6% SDS-PAGE gel, the target protein was
digested with trypsin and analyzed by tandem TOF MS. As a
result, the protein was strongly suggested to be ORF31 (Figure S3).
A difference of approximately 20 kDa was seen between
theoretical calculations (ca. 203 kDa) and experimental estimates
of the mw (ca. 183 kDa). Phage proteins are frequently N-
terminally processed and a start codon of the orf could be
mistakenly annotated, so the protein was N-terminally sequenced.
In-house BLASTP analysis of the N-terminal protein sequence of
ORF31 showed that the protein sequence matched the sequence
of the putative ORF31 from amino acids 5–14. Thus, ORF31 was
considered to be encoded by orf31 as formally predicted (Figure
S4). The first four amino acids at the N-terminal end appeared to
be processed or degraded. Thus, ORF31 was considered to be
encoded exactly as predicted using bioinformatics, and the
difference between the theoretical calculation and the experimen-
tal calculation of the mw was probably attributable to the behavior
of such a large protein on the SDS-PAGE.
Tail fiber of phage WEF24C
The large structural protein ORF31 was found to be associated
with adsorption, and bioinformatics analysis indicated that it was a
tail fiber. Thus, it was hypothesized that a tail fiber might be
present in phage WEF24C. However, a tail fiber was not observed
using conventional methods [16]. Thus, attempts were made to
observe the phage WEF24C tail end. Following the additional
wash step after loading the sample onto the formvar-coated copper
mesh, a flexible long tail fiber extending from the tail end was
observed in phage WEF24C (Figure 5A).
ORF31 as a possible component of a tail fiber
Using the purified anti-GP31:3680–5200 antibody, immunoe-
lectron microscopy was conducted. Several sample treatments
were involved in the immunoelectron microscopy, and the
immunogold-attached fine tail fiber of phage WEF24C was
difficult to observe. However, some electron micrographs showed
a tail fiber attached to a gold particle (Figure 5B). Therefore, these
facts strongly suggested that ORF31 was a component of the tail
fiber.
Improvement of in vitro therapeutic efficacy
Phage WEF24C has previously demonstrated in vivo thera-
peutic effects, so phage WEF24C mutants with sufficient
infectivity are expected to be therapeutically effective in vivo.
Thus, the bactericidal effects of phages WEF24C and WEF24C-P2
against E. faecalis strain EF11, which was less sensitive to phage
WEF24C, were measured in vitro. Phages WEF24C and WEF24C-
P2 were cultured with E. faecalis to yield a multiplicity of infection
(MOI) of 0.01 in TSB media. Phage WEF24C-P2 lysed bacteria
within 3 h, whereas phage WEF24C did not (Figure 6A). Next,
phage was cultured with bacteria to yield an MOI of 0.01 in
human blood. Phages WEF24C and WEF24C-P2 both success-
fully reduced bacterial concentration in human blood after
incubation for 24 h compared with no phage treatment, but the
mutant phage WEF24C-P2 showed a significantly greater
Figure 4. Structural protein analysis. Structural protein analysis
and Western blot with anti-ORF31 rabbit antisera, separated using (A)
12.5% and (B) 6% SDS-PAGE gels. SDS-PAGE images of the structural
proteins visualized by silver staining are shown in the left column. The
middle and right columns show the Western blot images created by
anti-GP31:2640–4150 and anti-GP31:3680–5200 rabbit antisera. The
arrows indicate the possible ORF31 protein band detected by the
Western blot analysis. (C) SDS-PAGE image of the concentrated phage
WEF24C proteins. Phage WEF24C proteins were concentrated by
100 kDa cutoff centrifugal ultrafiltration. The phage proteins were
electrophoresed using a 6% SDS-PAGE gel and visualized by colloidal
Coomassie G-250 staining. The arrow indicates the protein analyzed by
MALDI-TOF/TOF and N-terminal sequencing (see Figures S3 and S4).
doi:10.1371/journal.pone.0026648.g004
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type phage WEF24C after incubation for 24 h (Figure 6B). This
result suggests that the bactericidal activities of both phages were
not affected by the biological factors in the blood. Thus, the
mutant phage WEF24C-P2 was considered to have improved
therapeutic effects over the wild-type phage WEF24C, even in
human blood.
Discussion
Phage WEF24C-P2 was investigated because of the great
current interest in therapeutic phage development. Whole genome
sequence scanning detected a point mutation in orf31. This study
subsequently elucidated the presence of a tail fiber in phage
WEF24C and showed that ORF31 was a component of the long
tail fiber. SPO1-like viruses are important as therapeutic phages.
Tail fiber genes can be useful targets for genetic recombination in
future therapeutic phage development, so the tail fiber genes of
SPO1-like viruses are of interest. However, the putative proteins of
other SPO1-like viruses corresponding to ORF31 only showed
similarity to the N-terminal region of the ORF31, and their
molecular sizes were much smaller than that of ORF31 in some
cases. In addition, it was not known whether this long tail fiber was
unique to phage WEF24C. A review of previous studies showed
that two types of tail fibers were shown by electron microscopic
studies of the SPO1-like viruses: short tail fibers around the tail
edge, and a single long tail fiber extending from the tail end
[14,31,32]. Several short tail fibers have been seen in the Listeria
phage A511, but a long tail fiber has been reported only in the
Lactobacillus phage LP65 [31,32].
The essential proteins such as major structural proteins are
fairly conserved in the related phages, and functionally related
genes are closely aligned [38–40]. However, adsorption proteins
such as tail fiber proteins are expected to be diverse because they
respond to the various surface structures of bacterial species [41–
44]. Thus, a whole genome comparison of SPO1-like viruses was
conducted using BLASTP to estimate the presence of the genes
encoding for a tail fiber. According to the reciprocal genomic
comparison by BLASTP between SPO1-like viruses (Figure 7), the
homologous ORFs were clustered and the ORF arrangements
were also conserved. These conserved ORFs occupied 57% of the
ORFs on the phage WEF24C genome and were considered to be
essential in the phage structure. When the homologous proteins
Figure 6. The improved infectivity of phage WEF24C-P2. (A) Lytic activities of phages WEF24C and WEF24C-P2 in TSB media. E. faecalis strain
EF11 was incubated with/without phage at MOI 0.01. Changes in bacterial concentration were tracked over time and measured by optical density at
600 nm. The mean value is plotted, and the SD is shown as an error bar (n=3). (B) Antimicrobial activities of phages WEF24C and WEF24C-P2 in
human blood. E. faecalis strain EF11 was incubated with/without phage at MOI 0.01 for 24 h at 37uC, in human blood. After incubation, viable
bacteria were measured by colony counting. The bacterial concentration changes are shown as percentages. Error bars indicate SD (n=6). Two
groups of data sets were analyzed with the Mann-Whitney U test. The bacterial concentration was significantly reduced by the wild-type phage
WEF24C (P,0.05) and the mutant phage WEF24C-P2 (P,0.005) compared with that in the control group. Moreover, compared with the phage-
WEF24C-treated group, the phage-WEF24C-P2-treated group showed a significant reduction in the bacterial concentration (P,0.01). The gray line
indicates bacterial growth in the presence of phage WEF24C-P2. The black line indicates bacterial growth in the presence of phage WEF24C. The
dotted line indicates bacterial growth without the phage.
doi:10.1371/journal.pone.0026648.g006
Figure 5. Electron microscopic analysis of phage WEF24C. (A)
Electron microscopic analysis of phage WEF24C tail fiber. A single thin
tail fiber with a knob was observed at the tail end of phage WEF24C.
The length of the tail fiber was found to be 78.664.2 nm (n=8; mean 6
SD). In the left electron micrograph, a tail fiber was flexibly extended
from the tail of phage WEF24C. In the right electron micrograph, the
tips of the tail fibers appear to bind each other. Bars indicate 100 nm.
Arrows indicate tail fibers. (B) Immunoelectron microscopic analysis of
the ORF31 of phage WEF24C. Phage WEF24C was initially treated using
the anti-GP31:3680–5200 antibody, and then treated with the
immunogold-conjugated antibody. Gold particles were detected
around the tail end. In the left micrograph, a gold particle is located
on the tail fiber of phage WEF24C. In the middle and right micrographs,
a gold particle seems to be located around the tail, but the tail fiber is
not clearly visible. Bars indicate 100 nm.
doi:10.1371/journal.pone.0026648.g005
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26648Figure 7. Reciprocal genomic comparison of phage WEF24C with other SPO1-like viruses. Whole genome matrix analysis by BLASTP
assessed the arrangement of the similar ORFs, using Genome Matcher (http://www.ige.tohoku.ac.jp/joho/gmProject/gmhomeJP.html) [29]. The
phage WEF24C genome and other compared genomes are shown in the rows and the columns of each figure, respectively. The genomic direction is
shown left to right and top to bottom. Similarity is shown by size and the color of the circle. The degree of similarity is shown in color and a colored
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arrangements were linear, as can be seen in the matrices shown in
Figure 7. However, a nonhomologous region was present between
ORF31 and ORF34, which is shown as a gap in the matrices in
Figure 7. This gap in the linearity of the ORF arrangement
around ORF31 to ORF34 suggests that the genes corresponding
to orf31 to orf34 appeared to be present in Lactobacillus phages LP65
and WLb338-1, but missing in other SPO1-like viruses. This
suggests that the long tail fiber is likely to be present in Enterococcus
phages WEF24C and Lactobacillus phages LP65 and WLb338-1.
Therefore, it was concluded that some SPO1-like viruses might
have a long tail fiber.
In T-even phages such as phages T2 and T4, the tip of the long
tail fibers (i.e., the ligand) binds to the first molecules on the
bacterial surface (i.e., a receptor), and the tail pin is then
irreversibly attached to a second molecule on the bacterial surface
(i.e., a receptor). Phages T2 and T4 have tail fibers that are similar
in shape, but the ligand proteins of these tail fibers differ in
molecular weight and their function is slightly different. In phage
T4, one of the largest proteins, gp37, functions as both a tail fiber
shaft and a ligand protein [45,46]. In phage T2, a small protein,
gp38, binds to a tip of the long tail fiber and only functions as a
ligand protein [22,25]. In phage WEF24C, the ligand protein
genes are still unknown. This study and the reciprocal genome
study suggest that ORF31 and related proteins might be a ligand
component of tail fibers. Thus, recombinant proteins of ORF31 to
ORF34 might affect their binding ability. Recombinant proteins of
intact ORF31 and intact ORF32 were produced with some effort,
but these recombinant proteins were not expressed in Esc. coli (data
not shown). Subsequently, recombinant proteins of partially
deleted ORF31, partially deleted ORF32, and intact ORF33
were produced. However, these were insoluble, or they were
soluble but did not show binding activity to E. faecalis (data not
shown). Thus, further study is required to identify the ligand part
of the tail fiber. A ligand protein might require a chaperone
protein to fold correctly as seen in phage T4 [45,46], or a
heteromultimer may function as the ligand.
Such an increase in phage infectivity caused by a mutation is
not an unusual event. Phage and bacteria evolve in the context of a
coevolutionary arms race between the host cell defenses and the
phage counterdefenses, and the population dynamics of the phage
and the host bacteria can propel molecular evolution toward
adaptation and counteradaptation [47,48]. During the short-term
coevolution of bacteria and phages, bacteria modify their surface
structures, and phages tend to change their adsorption molecules
[49,50]. In this study, a phenotypically altered phage was
produced that managed to infect a bacterial strain that was
normally less sensitive to phage, during the short-term coevolution
of the phage and the bacterium. Therefore, such a coevolutionary
study of the relationship between the host cell defenses and the
phage counterdefenses should benefit the development of a
therapeutic phage and facilitate the future introduction of phage
therapies to Western countries.
Finally, the benefits of phage WEF24C-P2 in therapeutic use
were examined. The in vivo life-saving effects of phage WEF24C
were previously demonstrated, so in vivo therapeutic effects were
also expected of phage WEF24C-P2. In this study, phage WEF24C-
P2 showed significantly higher antimicrobial effects in TSB media
and human blood compared with phage WEF24C, particularly
against bacterial strains derived from urological infections (the type
of infection was unknown). The bacteriolytic activity of the wild-
type phage WEF24C seemed to be higher in human blood than in
TSB medium (Figure 6). Although the mechanisms underlying this
observation are not known, some unknown factors may increase
the infectivity, especially the adsorption ability, of the phage in
human blood. Urological infections caused by Enterococci are
generally difficult to treat, because the biofilm formed by
enterococcal cells impedes drug access to the site of infection
[51]. Thus, there are significant challenges for the treatment of
enterococcal infections in clinical settings. Fortunately, phage
therapy has recently proved its effectiveness against enterococcal
chronic prostatitis in clinical case studies [52,53]. Thus, phage
WEF24C-P2 might be a useful therapeutic phage against such
urological infections.
Tail fibers could be good targets for phage genetic modification
in therapeutic phage development, so the characterization of tail
fibers is considered important. The ligand part of the tail fiber has
not been identified, but this study suggested that ORF31 may be a
good target for phage genetic modification. Despite the long
history of research and its importance in phage therapy, this is the
first report of molecular characterization of a long tail fiber in
SPO1-like viruses.
Supporting Information
Figure S1 Bioinformatics analysis of ORF31 of phage
O ¨ EF24C and ORF122 of Lactobacillus paracasei phage
WLb338-1. At the N-terminal end, 53% of the ORF31 sequence
was similar to Lactobacillus phage WLb338-1 ORF122, with an E-
value of 1.0610
2114. No protein signature was found for ORF31.
The mutation site found in phage WEF24C-P2 is shown by an
asterisk. By contrast, the BLASTp on NCBI showed that the
ORF122 of Lactobacillus paracasei phage WLb338-1 was similar to
the putative tail host specificity proteins from phages or prophages
of intestinal bacteria in the C-terminal region (approximately from
amino acid 2000 to 2222). InterProScan predicted a galactose
binding domain-like superfamily for amino acids 1463–1606 in the
Lactobacillus phage WLb338-1 ORF122.
(EPS)
Figure S2 The recombinant proteins of ORF31. Two
recombinant proteins, GP31:2640–4150 and GP31:3680–5200,
were produced in Esc. coli. The mutation site found in phage
WEF24C-P2 is denoted by an asterisk. The form of the protein
(soluble or insoluble) is shown on the right.
(EPS)
Figure S3 MALDI-TOF/TOF analysis of the ORF31
protein identified by western blotting. The concentrated
protein, indicated by an arrow in Figure 5C, was analyzed by
MALDI-TOF/TOF. (A) Mass spectrum of the trypsin-digested
protein. Peptide peaks were are numbered on the top, were further
analyzed. (B) Summary of the MS/MS data. The data acquired
from each peak were analyzed by Paragon method using
ProteinPilot 3.0 software (AB Sciex) against the phage WEF24C
database. The protein was strongly suggested to be ORF31
scale bar is shown on the bottom right. In the top row of matrices, the ORF31 of phage WEF24C is numbered 31. The green boxes indicate the
structural protein region, including ORF31, but without similarities. Fifty-seven percent of the phage WEF24C genome was conserved in the ORF
arrangement compared with the SPO1-like viruses. In ORF31, a different level of similarity was observed. However, ORF122 of Lactobacillus phage
WLb338-1 and ORF97 of Lactobacillus phage LP65 were similar to ORF31 in terms of molecular size and N-terminal protein sequence. No similarity to
other ORFs of the SPO1-like viruses was observed for ORF32–ORF34.
doi:10.1371/journal.pone.0026648.g007
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16.6%; No. of pepetide with 95% confidence, 14).
(EPS)
Figure S4 N-terminal sequence of ORF31. The concen-
trated protein indicated in Figure 5C was N-terminally sequenced.
The putative ORF31 and N-terminal sequences of the ORF31 are
shownat the top and bottom,respectively. Aminoacidsareshownas
a single letter. X indicates an unknown. The N-terminal amino acid
sequence was analyzed against the putative ORF31 by in-house
BLASTp search using Genetyx version 10 (Genetyx Corporation).
The matched sequence is highlighted in gray. ORF31 appeared to
start from the amino acid 5 of the putative ORF31. The first four
amino acids from the N-terminal may be posttranslationally
processed, or might be lost by degradation of the protein.
(EPS)
Table S1 PCR primers for identifying genomic frag-
ments.
(PDF)
Table S2 List of genome sequencing primers.
(PDF)
Table S3 Primers used for cloning the genes of partial
orf31.
(DOC)
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